Temsirolimus maintenance therapy after docetaxel induction in castration-resistant prostate cancer

Oncologist

Volumn 20, Issue 12, 2015, Pages 1351-1352

  Emmenegger, Urban ^a   Booth, Christopher M ^b   Berry, Scott ^a   Sridhar, Srikala S ^a   Winquist, Eric ^c   Bandali, Nesan ^a   Chow, Annabelle ^a   Lee, Christina ^a   Xu, Ping ^a   Man, Shan ^a   Kerbel, Robert S ^a   Ko, Yoo Joung ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; RAPAMYCIN; TAXOID;

ARTICLE; ASSESSMENT OF HUMANS; CASTRATION RESISTANT PROSTATE CANCER; DRUG RESPONSE; DRUG SAFETY; FUNCTIONAL ASSESSMENT OF CANCER THERAPY PROSTATE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRESENT PAIN INTENSITY SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; SIROLIMUS; TAXOIDS; TREATMENT OUTCOME;

EID: 84949993498     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0220     Document Type: Article

References (0)